Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-02T20:32:58.340Z Has data issue: false hasContentIssue false
  • English
  • Français

The need for routine physical health care in schizophrenia

Published online by Cambridge University Press:  16 April 2020

A.-L. Montejo
A.-L. Montejo*
Affiliation:
University of Salamanca, Av Comuneros 27. Salamanca, Spain
*
Correspondence. Tel.: +34 923 126596/97. E-mail address: [email protected]
Get access

Abstract

When managing their patients with schizophrenia, psychiatrists are increasingly concerned about physical disorders, including weight gain, obesity, metabolic abnormalities (in particular, diabetes and the metabolic syndrome), prolactin increase, sexual dysfunction and cardiovascular disease. Other common health-related problems in these patients include recreational drug use, sedation/physical inactivity, adverse drug effects and poor self-care. Each of these can have an impact on patient well-being, adherence to therapy and life expectancy. Collectively they can pose substantial barriers to optimal outcomes. However, the widespread acknowledgement of the importance of the physical health of patients with schizophrenia does not always result in consistent monitoring and management of physical health risks in the clinic. Urgent action is needed to ensure that psychiatrists prioritise physical healthcare alongside mental healthcare as a way to improve the longterm outcomes of treatment in all patients with schizophrenia.

Keywords

SchizophreniaAntipsychotic agentsPhysical health
Type
Research Article
Information
European Psychiatry , Volume 25 , Issue S2: Physical health in patients with schizophrenia: current knowledge and practical recommendations , June 2010 , pp. S3 - S5
Copyright
Copyright © 2010 Elsevier Masson SAS

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allison, D.B.Mentore, J.L.Heo, M.Chandler, L.P.Cappelleri, J.C.Infante, M.C., et al.Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–1696Google ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601CrossRefGoogle Scholar
Balkau, B.Deanfield, J.E.Despres, J.P.Bassand, J.P.Fox, K.A.Smith, S.C. Jr., et al.International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007; 116: 1942–1951CrossRefGoogle ScholarPubMed
Basson, R.Rees, P.Wang, R.X.Montejo, A.L.Incrocci, L.Sexual Function in Chronic Illness. J Sexual Medicine 2010; 7: 374–388CrossRefGoogle ScholarPubMed
Buckley, P.F.Miller, dD.Singer, B.Arena, J.Stirewalt, E.M.Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79: 281–288CrossRefGoogle ScholarPubMed
Casey, D.E.Haupt, D.W.Newcomer, J.W.Henderson, D.C.Sernyak, M.J.Davidson, M., et al.Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65(Suppl. 7): 4–18Google ScholarPubMed
Chue, P.Cheung, R.The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta Neuropsychiatrica 2004; 16: 113–123CrossRefGoogle Scholar
Citrome, L.Yeomans, D.Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005; 19: 102–109CrossRefGoogle ScholarPubMed
De Hert, M.van Winkel, R.van Eyck, D.Hanssens, L.Wampers, M.Scheen, A., et al.Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2006; 2: 14CrossRefGoogle ScholarPubMed
Han, T.S.Van Leer, E.M.Seidell, J.C.Lean, M.E.Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 1401–1405CrossRefGoogle ScholarPubMed
Leucht, S.Burkard, T.Henderson, J.Maj, M.Sartorius, N.Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116: 317–333CrossRefGoogle ScholarPubMed
McIntyre, R.S.Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry 2009; 70Suppl 3: 5–11CrossRefGoogle ScholarPubMed
McIntyre, RSStave, CO’Brien, CJina, ASChang, L. UNITE = Understanding Needs, Interactions, Treatment and Expectations: a global survey of carers and patients with scizophrenia and bipolar disorder. Poster presented at the 15th Association of European Psychiatrists meeting, Madrid, Spain, 17-21 March 2007.CrossRefGoogle Scholar
Montejo, A.L.Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 2008; 18Suppl 2: S108–S114CrossRefGoogle Scholar
Montejo, A.L.Majadas, S.Rico-Villademoros, F.Llorca, G.De La Gándara, J.Franco, M.Martín-Carrasco, M.Aguera, L.Prieto, N.for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sexual Medicine 2010 [Epub ahead of print] PMID 20214720Google ScholarPubMed
Montejo, A.L.Rico-Villademoros, F.Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQSALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 2008; 34: 227–239CrossRefGoogle Scholar
Nasrallah, H.A.Meyer, J.M.Goff, D.C.McEvoy, J.P.Davis, S.M.Stroup, T.S., et al.Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15–22CrossRefGoogle ScholarPubMed
Osby, U.Correia, N.Brandt, L.Ekbom, A.Sparen, P.Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21–28CrossRefGoogle ScholarPubMed
Weiden, P.J.Mackell, J.A.McDonnell, D.D.Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51–57CrossRefGoogle ScholarPubMed
Yusuf, S.Hawken, S.Ounpuu, S.Bautista, L.Franzosi, M.G.Commerford, P., et al.Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640–1649CrossRefGoogle ScholarPubMed
Yusuf, S.Hawken, S.Ounpuu, S.Dans, T.Avezum, A.Lanas, F., et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.